Primerdesign[™]Ltd

Human Parvovirus B19 (HPVB19)

NS1 protein

genesig® Standard Kit

150 tests



Kits by Primerdesign

1

For general laboratory and research use only

Quantification of Human Parvovirus B19 (HPVB19) genomes. genesig Standard kit handbook HB10.04.10 Published Date: 09/11/2018

Introduction to Human Parvovirus B19 (HPVB19)

Parovirus B19 is a single stranded DNA virus of the Parvoviridae family. The positive-sense linear DNA of approximately 5.5Kbp is surrounded by an icosahedral capsid with a diameter of 18-26nm. This virus is part of the Erythrovirus genus as it is capable of invading red blood cell precursors in the bone marrow.

Infected respiratory droplets transmit the virus between people in close contact, although blood-borne transmission may also occur. The virus attaches to the host cells via a capsid protein and moves to the host cell nucleus where the viral genome is replicated. The host cells targeted by this virus can include any tissue perfused by blood, but replication only occurs in the bone marrow or in the fetal liver as these are the sites of erythropoeisis. Cell death of infected cells is thought to be a result of cytotoxicity occurring from non-structural viral proteins. Once infected, a person is contagious before symptoms develop. There is currently no vaccine available against this virus. Around 60% of adults have previously been infected with the virus which results in immunity.

Infection with Parovirus B19 can cause several diseases, namely: Erythema Infectiosium, more commonly known as fifth disease; Aplastic Crisis; Hydrops Fetalis and Arthropathy but 25% of cases can remain asymptomatic.

Fifth Disease most commonly occurs in children, it has an incubation period of 13-20 days, usually presenting with fever, malaise and a characteristic rash of the cheeks which later spreads to the extremities and can last up to 3 weeks. Infection in adults may lead to Arthropathy that can typically cause pain for between 2 days and 2 months but may be misdiagnosed as arthritis.

Infection of patients with a reduced healthy red blood cell count, such as in sickle cell disease, may result in transient aplastic crisis as the virus is known to reduce erythropoiesis, patients in this position may require a blood transfusion.

In pregnant women, infection can lead to Hydrops Fetalis resulting in miscarriage or still birth. The risk of fetal loss is dependant on when during the pregnancy the infection occurs, although even at the highest, this risk is about 10%.


Specificity

The Primerdesign genesig Kit for Human Parvovirus B19 (HPVB19) (HPVB19) genomes is designed for the in vitro quantification of HPVB19 genomes. The kit is designed to have a broad detection profile. Specifically, the primers represent 100% homology with over 95% of the NCBI database reference sequences available at the time of design.

The dynamics of genetic variation means that new sequence information may become available after the initial design. Primerdesign periodically reviews the detection profiles of our kits and when required releases new versions.

The primers and probe have 100% homology with over 95% of reference sequences in the NCBI database including the small subset shown below.

If you require further information, or have a specific question about the detection profile of this kit then please send an e.mail to enquiry@primerdesign.co.uk and our bioinformatics team will answer your question.



Kit contents

- HPVB19 specific primer/probe mix (150 reactions BROWN) FAM labelled
- HPVB19 positive control template (for Standard curve RED)
- RNase/DNase free water (WHITE)
 for resuspension of primer/probe mixes
- Template preparation buffer (YELLOW) for resuspension of positive control template and standard curve preparation

Reagents and equipment to be supplied by the user

Real-time PCR Instrument

Extraction kit

This kit is recommended for use with genesig Easy DNA/RNA extraction kit. However, it is designed to work well with all processes that yield high quality RNA and DNA with minimal PCR inhibitors.

oasig[™] lyophilised or Precision[®]PLUS 2X qPCR Master Mix

This kit is intended for use with oasig or PrecisionPLUS2X qPCR Master Mix.

Pipettors and Tips

Vortex and centrifuge

Thin walled 1.5 ml PCR reaction tubes

Kit storage and stability

This kit is stable at room temperature but should be stored at -20°C on arrival. Once the lyophilised components have been resuspended they should not be exposed to temperatures above -20°C for longer than 30 minutes at a time and unnecessary repeated freeze/thawing should be avoided. The kit is stable for six months from the date of resuspension under these circumstances.

If a standard curve dilution series is prepared this can be stored frozen for an extended period. If you see any degradation in this serial dilution a fresh standard curve can be prepared from the positive control.

Primerdesign does not recommend using the kit after the expiry date stated on the pack.

Suitable sample material

All kinds of sample material suited for PCR amplification can be used. Please ensure the samples are suitable in terms of purity, concentration, and DNA integrity. Always run at least one negative control with the samples. To prepare a negative-control, replace the template DNA sample with RNase/DNase free water.

Dynamic range of test

Under optimal PCR conditions genesig HPVB19 detection kits have very high priming efficiencies of >95% and can detect less than 100 copies of target template.

Notices and disclaimers

This product is developed, designed and sold for research purposes only. It is not intended for human diagnostic or drug purposes or to be administered to humans unless clearly expressed for that purpose by the Food and Drug Administration in the USA or the appropriate regulatory authorities in the country of use. During the warranty period Primerdesign genesig detection kits allow precise and reproducible data recovery combined with excellent sensitivity. For data obtained by violation to the general GLP guidelines and the manufacturer's recommendations the right to claim under guarantee is expired. PCR is a proprietary technology covered by several US and foreign patents. These patents are owned by Roche Molecular Systems Inc. and have been sub-licensed by PE Corporation in certain fields. Depending on your specific application you may need a license from Roche or PE to practice PCR. Additional information on purchasing licenses to practice the PCR process may be obtained by contacting the Director of Licensing at Roche Molecular Systems, 1145 Atlantic Avenue, Alameda, CA 94501 or Applied Biosystems business group of the Applera Corporation, 850 Lincoln Centre Drive, Foster City, CA 94404. In addition, the 5' nuclease assay and other homogeneous amplification methods used in connection with the PCR process may be covered by U.S. Patents 5,210,015 and 5,487,972, owned by Roche Molecular Systems, Inc, and by U.S. Patent 5,538,848, owned by The Perkin-Elmer Corporation.

Trademarks

Primerdesign[™] is a trademark of Primerdesign Ltd.

genesig[®] is a registered trademark of Primerdesign Ltd.

The PCR process is covered by US Patents 4,683,195, and 4,683,202 and foreign equivalents owned by Hoffmann-La Roche AG. BI, ABI PRISM® GeneAmp® and MicroAmp® are registered trademarks of the Applera Genomics (Applied Biosystems Corporation). BIOMEK® is a registered trademark of Beckman Instruments, Inc.; iCycler[™] is a registered trademark of Bio-Rad Laboratories, Rotor-Gene is a trademark of Corbett Research. LightCycler[™] is a registered trademark of the Idaho Technology Inc. GeneAmp®, TaqMan® and AmpliTaqGold® are registered trademarks of Roche Molecular Systems, Inc., The purchase of the Primerdesign reagents cannot be construed as an authorization or implicit license to practice PCR under any patents held by Hoffmann-LaRoche Inc.

Principles of the test

Real-time PCR

A HPVB19 specific primer and probe mix is provided and this can be detected through the FAM channel.

The primer and probe mix provided exploits the so-called TaqMan® principle. During PCR amplification, forward and reverse primers hybridize to the HPVB19 DNA. A fluorogenic probe is included in the same reaction mixture which consists of a DNA probe labeled with a 5`-dye and a 3`-quencher. During PCR amplification, the probe is cleaved and the reporter dye and quencher are separated. The resulting increase in fluorescence can be detected on a range of qPCR platforms.

Positive control

For copy number determination and as a positive control for the PCR set up, the kit contains a positive control template. This can be used to generate a standard curve of HPVB19 copy number / Cq value. Alternatively the positive control can be used at a single dilution where full quantitative analysis of the samples is not required. Each time the kit is used, at least one positive control reaction must be included in the run. A positive result indicates that the primers and probes for detecting the target HPVB19 gene worked properly in that particular experimental scenario. If a negative result is obtained the test results are invalid and must be repeated. Care should be taken to ensure that the positive control does not contaminate any other kit component which would lead to false-positive results. This can be achieved by handling this component in a Post PCR environment. Care should also be taken to avoid cross-contamination of other samples when adding the positive control to the run. This can be avoided by sealing all other samples and negative controls before pipetting the positive control well.

Negative control

To validate any positive findings a negative control reaction should be included every time the kit is used. For this reaction the RNase/DNase free water should be used instead of template. A negative result indicates that the reagents have not become contaminated while setting up the run.

Resuspension protocol

To minimize the risk of contamination with foreign DNA, we recommend that all pipetting be performed in a PCR clean environment. Ideally this would be a designated PCR lab or PCR cabinet. Filter tips are recommended for all pipetting steps.

1. Pulse-spin each tube in a centrifuge before opening.

This will ensure lyophilised primer and probe mix is in the base of the tube and is not spilt upon opening the tube.

2. Resuspend the kit components in the RNase/DNase free water supplied, according to the table below.

To ensure complete resuspension, vortex each tube thoroughly.

Component - resuspend in water	Volume
Pre-PCR pack	
HPVB19 primer/probe mix (BROWN)	165 µl

3. Resuspend the positive control template in the template preparation buffer supplied, according to the table below:

To ensure complete resuspension, vortex the tube thoroughly.

Component - resuspend in template preparation buffer	
Post-PCR heat-sealed foil	
HPVB19 Positive Control Template (RED) *	500 µl

* This component contains high copy number template and is a VERY significant contamination risk. It must be opened and handled in a separate laboratory environment, away from the other components.

qPCR detection protocol

1. For each DNA sample prepare a reaction mix according to the table below: Include sufficient reactions for positive and negative controls.

Component	Volume
oasig or PrecisionPLUS 2X qPCR Master Mix	10 µl
HPVB19 primer/probe mix (BROWN)	1 µl
RNase/DNase free water (WHITE)	4 µl
Final Volume	15 µl

- 2. Pipette 15µl of this mix into each well according to your qPCR experimental plate set up.
- 3. Prepare DNA templates for each of your samples.
- 4. Pipette 5µl of DNA template into each well, according to your experimental plate set up.

For negative control wells use 5µl of RNase/DNase free water. The final volume in each well is 20µl.

5. If a standard curve is included for quantitative analysis, prepare a reaction mix according to the table below:

Component	Volume
oasig or PrecisionPLUS 2X qPCR Master Mix	10 µl
HPVB19 primer/probe mix (BROWN)	1 µl
RNase/DNase free water (WHITE)	4 µl
Final Volume	15 µl

6. Preparation of a standard curve dilution series.

- 1) Pipette 90µl of template preparation buffer into 5 tubes and label 2-6
- 2) Pipette 10µl of Positive Control Template (RED) into tube 2
- 3) Vortex thoroughly
- 4) Change pipette tip and pipette 10µl from tube 2 into tube 3
- 5) Vortex thoroughly

Repeat steps 4 and 5 to complete the dilution series

Standard Curve	Copy Number *
Tube 1 Positive control (RED)	2 x 10⁵ per µl
Tube 2	2 x 10⁴ per µl
Tube 3	2 x 10³ per µl
Tube 4	2 x 10² per µl
Tube 5	20 per µl
Tube 6	2 per µl

*The quantitative results produced by the genesig HPVB19 kit can be converted to International Units by multiplying copy numbers by 1.53. This conversion factor was developed using RNA/DNA extracted (where applicable) from the WHO International Standard for HPVB19.

Users of this kit are advised that the conversion factor serves as a guide. For the highest level of accuracy, it is best practice to calculate conversion factors independently using the WHO International Standard. If unsure, please contact your local sales representative for details regarding the generation of the conversion factor to ensure it is applied in the most appropriate fashion.

 Pipette 5µl of standard template into each well for the standard curve according to your experimental plate set up.
 The final values in each well is 20µl

The final volume in each well is 20µl.

qPCR amplification protocol

Amplification conditions using oasig or PrecisionPLUS2X qPCR Master Mix.

Step		Time	Temp
	Enzyme activation	2 min	95 °C
Cycling x50	Denaturation	10 s	95 °C
	DATA COLLECTION *	60 s	60 °C


* Fluorogenic data should be collected during this step through the FAM channel

Interpretation of results


Target	Positive control	Negative control	Interpretation
+	+	-	POSITIVE QUANTITATIVE RESULT calculate copy number
-	+	-	NEGATIVE RESULT
+/-	+	≤ 35	EXPERIMENT FAILED due to test contamination
+/-	+	> 35	*
+/-	-	+/-	EXPERIMENT FAILED

Positive control template (RED) is expected to amplify between Cq 16 and 23. Failure to satisfy this quality control criterion is a strong indication that the experiment has been compromised

*Where the test sample is positive and the negative control is positive with a Cq > 35, the sample must be reinterpreted based on the relative signal strength of the two results:



If the sample amplifies > 5 Cq earlier than the negative control then the sample should be reinterpreted (via the table above) with the negative control verified as negative.



If the sample amplifies < 5 Cq earlier than the negative control then the positive sample result is invalidated and the result should be determined inconclusive due to test contamination. The test for this sample should be repeated.